Thermo Fisher Scientific Expands Viral Vector Manufacturing at Plainville, Massachusetts, Facility
05/12/2020
According to company officials, the $180 million project will more than double the company's commercial viral vector capacity to support increasing demand for the development and manufacture of gene therapies and vaccines.
Construction of the new 290,000-square-foot facility is expected to be completed in 2022. The project will add more than 200 jobs and complement the company's new or recently expanded capacity in Lexington and Cambridge, Massachusetts, and Alachua, Florida.
"The Plainville expansion significantly enhances our 'start here, stay here' strategy, ensuring that customers have an uninterrupted pathway from development through commercialization," said Michel Lagarde, executive vice president of Thermo Fisher Scientific. "Between Plainville and our other expanded sites in the U.S., we're increasing viral vector production to accelerate cell and gene therapy innovation, giving hope to more patients everywhere."
The Plainville site will offer a flexible and scalable configuration of laboratory and production suites co-located with adjacent warehousing and office space. An onsite engineering laboratory will help customers develop turnkey production platforms that enable them to rapidly transition to commercial-scale operations when ready. As with its other viral vector development and manufacturing sites, Thermo Fisher's Plainville site will attract a diverse workforce of scientists, quality control specialists and production teams.
Thermo Fisher strategically selected Plainville to capitalize on its expertise at other Massachusetts locations and draw upon the strong talent pool in the Greater Boston area. The state-of-the-art facility will feature digital connectivity and capabilities that enable operational efficiencies, high quality, data visibility and advanced operator training.
Lagarde added, "The global race to develop new transformative medicines illustrates how important it is for our customers to have access to surge capacity as well as flexibility to adapt and change therapeutic platforms, whether they are developing a new viral vector for a novel therapy or the next life-saving cancer treatment."
Project Announcements
Bartlett Group Plans Strathcona County, Alberta, Headquarters-Manufacturing Operations
10/11/2024
Mart Frozen Foods Establishes Rupert, Idah, Production Operations
10/11/2024
Verst Group Logistics Expands Boone County, Kentucky, Operations
10/11/2024
Afton Scientific Expands Albemarle County, Virginia, Manufacturing Operations
10/10/2024
Eli Lilly and Company Expands Lebanon, Indiana, Operations
10/09/2024
Johnson & Johnson Plans Wilson, North Carolina, Pharmaceutical Manufacturing Operations
10/08/2024
Most Read
-
Top States for Doing Business in 2024: A Continued Legacy of Excellence
Q3 2024
-
Cold Storage: The Next Big Thing in Industrial Real Estate
Q3 2024
-
What the Latest EPA PFAS Rule Means for Site Due Diligence
Q3 2024
-
Reaching for the Stars: Space Industry Creating Opportunities Across the Country
Q3 2024
-
2023 Top States for Doing Business Meet the Needs of Site Selectors
Q3 2023
-
2023's Leading Metro Locations: Hotspots of Economic Growth
Q4 2023
-
Mitigating Site Risks for Industrial Projects
Q3 2024